US Patent No: 7,846,725

Number of patents in Portfolio can not be more than 2000

Antibody composition-producing cell in which enzyme expression is inhibited by RNAi

ALSO PUBLISHED AS: 20080261301
1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
KYOWA HAKKO KIRIN CO., LTD.TOKYO249

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hanai, Nobuo Machida, JP 135 1220
Hosaka, Emi Machida, JP 76 757
Kanda, Yutaka Machida, JP 118 995
Nakamura, Kazuyasu Machida, JP 131 1023
Satoh, Mitsuo Machida, JP 71 689
Shinkawa, Toyohide Machida, JP 60 779
Uchida, Kazuhisa Machida, JP 69 848
Yamane, Naoko Machida, JP 59 759
Yamano, Kazuya Machida, JP 56 482
Yamasaki, Motoo Machida, JP 123 1027

Cited Art Landscape

Patent Info (Count) # Cites Year
 
KYOWA HAKKO KIRIN CO., LTD. (36)
5,830,470 Humanized antibodies to ganglioside GM.sub.2 45 1993
6,018,032 Antibody against human interleukin-5-receptor .alpha. chain 34 1997
6,437,098 Human chimeric antibody specific for the ganglioside GD3 25 1999
6,986,890 Anti-human VEGF receptor Flt-1 monoclonal antibody 30 1999
6,989,145 Recombinant antibody and antibody fragment 35 2001
6,946,292 Cells producing antibody compositions with increased antibody dependent cytotoxic activity 83 2001
2003/0175,273 Human CDR-grafted antibody and antibody fragment thereof 27 2002
7,691,568 Antibody composition-containing medicament 10 2003
2004/0110,282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost 41 2003
2004/0132,140 Production process for antibody composition 51 2003
7,691,810 Method of producing recombinant antithrombin III composition 10 2004
2005/0187,380 Method for treating Th2-mediated disease 22 2005
7,214,775 Method of modulating the activity of functional immune molecules 64 2005
7,708,992 Methods for producing antibody compositions with increased ADCC 12 2005
2005/0272,916 Method of modulating the activity of functional immune molecules 34 2005
2006/0024,800 Method of modulating the activity of functional immune molecules 29 2005
2005/0216,958 Cells of which genome is modified 25 2005
2005/0262,593 Antibody composition-producing cell 28 2005
2006/0223,147 Process for producing glycoprotein composition 25 2005
2006/0063,254 Antibody composition-producing cell 33 2005
2006/0064,781 Antibody composition-producing cell 35 2005
7,393,683 Mammalian host cell modified by RNAi to inhibit .alpha. 1,6-fucosyltransferase 16 2005
7,425,446 Antibody composition-producing cell 17 2005
7,709,234 α-1,3-fucosyltransferase 11 2006
2007/0148,165 Recombinant antibody composition 18 2006
7,651,688 Method of modulating the activity of functional immune molecules to CD52 11 2007
7,655,228 Method of modulating the activity of functional immune molecules to GM2 11 2007
7,682,610 Method of modulating the activity of functional immune molecules 11 2007
7,682,611 Method of modulating the activity of functional immune molecules to CXCR4 protein 11 2007
7,708,997 Method of modulating the activity of functional immune molecules 11 2007
2007/0166,300 Method of Modulating the Activity of Functional Immune Molecules 24 2007
2007/0166,301 Method of Modulating the Activity of Functional Immune Molecules 24 2007
2007/0166,302 Method of Modulating the Activity of Functional Immune Molecules 24 2007
2007/0166,303 Method of Modulating the Activity of Functional Immune Molecules 24 2007
2007/0166,304 Method of Modulating the Activity of Functional Immune Molecules 24 2007
2008/0261,301 Antibody Composition-Producing Cell 22 2008
 
KYOWA HAKKO KOGYO CO., LTD. (5)
2004/0093,621 Antibody composition which specifically binds to CD20 75 2002
2004/0110,704 Cells of which genome is modified 52 2003
2005/0160,485 Mouse in which genome is modified 22 2004
2005/0226,867 IL-5R-specific antibody composition 23 2004
2005/0287,138 CCR4-specific antibody composition 24 2004
 
ROCHE GLYCART AG (5)
6,602,684 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 112 1999
2004/0072,290 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 56 2003
2005/0074,843 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 40 2003
2005/0079,605 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 36 2003
2007/0111,281 Antigen binding molecules having modified Fc regions and altered binding to Fc receptors 33 2006
 
Genentech, Inc. (4)
4,816,567 Recombinant immunoglobin preparations 1632 1983
6,169,070 Mer receptor activation by gas6 71 1996
6,737,056 Polypeptide variants with altered effector function 215 2000
7,297,775 Polypeptide variants 36 2002
 
ICOS CORPORATION (3)
5,880,268 Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18 30 1995
5,932,703 Macrophage derived chemokine and chemokine analogs 36 1996
6,498,015 Methods of identifying agents that modulate the binding between MDC and an MDC receptor 31 1997
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
6,488,930 Anti-CCR4 antibodies and methods of use therefor 33 1999
7,138,117 Anti-CCR4 antibodies and methods of use therefor 23 2002
 
PANASONIC CORPORATION OF NORTH AMERICA (2)
7,687,061 Method of modulating the activity of functional immune molecules to Her-2 11 2007
2007/0166,305 Method of Modulating the Activity of Functional Immune Molecules 24 2007
 
TANIGUCHI, NAOYUKI (2)
6,054,304 .alpha.1-6 fucosyltransferase 46 1998
6,291,219 .alpha.1-6 fucosyltransferase 22 1999
 
TOUDAI TLO, LTD. (2)
2004/0002,077 siRNA expression system and method for producing functional gene knock-down cell using the system 62 2002
2005/0048,647 Sirna expression system and process for producing functional gene knockdown cell or the like using the same 45 2004
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2)
5,977,316 Monoclonal antibody 1A7 and related polypeptides 30 1996
5,935,821 Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma 44 1996
 
ACTIVCARD IRELAND LIMITED (1)
7,502,497 Method and system for extracting an area of interest from within an image of a biological surface 19 2007
 
BIOGEN IDEC MA INC. (1)
7,033,589 γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics 24 1999
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,272,070 Method for the preparation of cell lines producing Man.sub.3 GlcN.sub.ac 2 asparagine-linked gylcans and cell lines produced thereby 59 1991
 
Boehringer Mannheim GmbH (1)
5,453,363 Process for the activation of t-PA or Ing after genetic expression in prokaryotes 35 1994
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
4,350,683 Antibody production from hybrid cell line 73 1980
 
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY (1)
6,540,980 Method of detecting endometriosis 25 2000
 
CENTRO DE INMUNOLOGIA MOLECULAR (1)
5,891,996 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use 87 1995
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
2003/0190,316 Stabilized antibody-containing preparations 59 2003
 
Desmos, Inc. (1)
5,658,789 Promotion of epithelial cell adhesion and hemidesmosome assembly by a laminin-like molecule 28 1995
 
DOVETAIL TECHNOLOGIES INC. (1)
6,762,174 Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof 21 1999
 
FUJITSU LIMITED (1)
6,189,781 Terminal unit having function for converting commodity information into bar code and vice versa 31 1994
 
GENENEWS INC. (1)
2005/0208,519 Biomarkers for diagnosing schizophrenia and bipolar disorder 12 2004
 
GENETICS INSTITUTE, LLC (1)
5,728,568 Human GDP-mannose 4,6 dehydratase 30 1996
 
GLAXO GROUP LIMITED (1)
6,150,132 Chemokine receptor able to bind to MCP-1, MIP-1.alpha. and/or RANTES. Its uses 41 1997
 
GLAXOSMITHKLINE LLC (1)
5,783,184 Method for treatment and diagnosis of IL-5 mediated disorders 15 1996
 
Hazleton Biotechnologies, Inc. (1)
4,757,018 Myeloma cell lines and uses thereof 28 1985
 
IDEC PHARMACEUTICALS CORPORATION (1)
6,455,043 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody 63 1999
 
LEUKOSITE, INC. (1)
6,245,332 Modulation of systemic memory T cell trafficking 31 1999
 
LONZA GROUP AG (1)
5,672,502 Animal cell culture 35 1995
 
MARIEL THERAPEUTICS, INC. (1)
5,614,385 Methods and compositions for high protein production from recombinant DNA 30 1995
 
MEDAREX, INC. (1)
5,922,845 Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies 83 1996
 
OSAKA UNIVERSITY (1)
2003/0170,813 Process for producing glycoprotein 23 2003
 
SMITHKLINE BEECHAM P.L.C. (1)
6,129,913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders 26 1997
 
SRD PHARMACEUTICALS, INC. (1)
5,665,569 HIV immunotherapeutics 36 1994
 
TAKATSU, KIYOSHI (1)
5,916,767 DNA encoding human interleukin-5 receptor 12 1997
 
THE GENERAL HOSPITAL CORPORATION (1)
5,858,983 Inhibition of cell adhesion protein-carbohydrate interactions 41 1995
 
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (1)
6,238,894 .alpha.1,2 fucosyltransferase 26 1999
 
The Green Cross Corporation (1)
4,721,777 Process for the virus-inactivation of immunoglobulin 37 1985
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (1)
6,350,868 Antisense human fucosyltransferase sequences and methods of use thereof 24 2000
 
THERMO FISHER SCIENTIFIC INC. (1)
2007/0031,844 Functional and hyperfunctional siRNA 317 2003
 
UNIVERSITY OF UTAH (1)
5,464,764 Positive-negative selection methods and vectors 227 1993
 
WISTAR INSTITUTE, THE, A CORP. OF PA (1)
4,849,509 Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies 50 1987
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
KYOWA HAKKO KIRIN CO., LTD. (9)
8,067,232 Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase 0 2008
8,158,760 Glycoengineered, recombinant antibody 0 2009
8,039,595 Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation 2 2009
8,367,407 Cells with altered fucosylation and producing antibodies therefrom 0 2009
8,679,491 Method of modulating the activity of functional immune molecules 0 2009
8,110,195 Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody 0 2010
* 8,101,185 Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation 0 2010
* 8,329,443 Antibody composition-producing cell 0 2011
8,895,266 Antibody composition-producing cell 0 2012
 
BIOWA, INC. (1)
8,501,176 Methods of reducing eosinophil levels 0 2011
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 7, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 7, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00